GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
AACR 2024 – Astra plays up PARP1 inhibition
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
